Dafhne Miranda-Hernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dafhne Miranda-Hernández has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Miguel Ángel Saavedra
Division of Health Research, Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, IMSS, CDMX, 02990, México
3 shared publications - Luis J. Jara
Direction of Education and Investigation, Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, IMSS, Seris y Zaachila s/n, Col. La Raza, Del. Azcapotzalco, 02990, Mexico City, Mexico
2 shared publications - María Pilar Cruz-Domínguez
Instituto Mexicano del Seguro Social, Centro Médico Nacional La Raza, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Dirección de Educación e Investigación en Salud. Ciudad de México, México
2 shared publications - Michelle Arrucha-Cozaya
Facultad de Medicina Benemérita Universidad Autónoma de Puebla Puebla Mexico
2 shared publications A Lara-Mejía
Rheumatology
1 shared publicationA Sánchez
Rheumatology
1 shared publication
Latest Publications
- 12 May 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 167 (1) , 420-426
Active but not quiescent lupus nephritis during pregnancy is associated with a higher rate of adverse obstetric outcomes: Analysis of a prospective cohort
Objective: To compare the maternal‐fetal/neonatal outcome in patients with systemic lupus erythematosus (SLE) with and without lupus nephritis (LN) in remission or with active disease. Methods: A prospective cohort of pregnant patients with SLE (ACR 1997 criteria) was studied from January 2009 to December 2021. Demographic, clinical, biochemical, and immunological variables as well as the usual maternal‐fetal/neonatal complications were recorded. We compared four groups according to the status of SLE during pregnancy: patients with quiescent SLE without lupus nephritis, patients with active SLE without lupus nephritis, patients with quiescent lupus nephritis, and patients with active lupus nephritis. Statistical analysis included descriptive statistics, bivariate analysis, and Cox regression analysis. Results: A total of 439 pregnancies were studied, with a median age of 28 ± 6, SLE duration of 60 months (interquartile range 36–120). A higher frequency of maternal and fetal/neonatal complications was observed in patients with active SLE with or without lupus nephritis. Multivariate analysis showed that active LN was a risk factor for gestational hypertension (hazard ratios [HR] 1.95; 95% confidence intervals [CI]: 1.01–6.39), premature rupture of membranes (HR 3.56; 95% CI: 1.79–16.05) and more frequent cesarean section (HR 1.82; 95% CI: 1.13–2.94). Conclusion: LN is associated with a higher frequency of maternal complications, especially in those patients with active disease during pregnancy, and those maternal complications had an impact on poor fetal/neonatal outcomes. Strict control and timely care of LN could improve the obstetric prognosis.
- 12 May 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 167 (1) , 420-426
Active but not quiescent lupus nephritis during pregnancy is associated with a higher rate of adverse obstetric outcomes: Analysis of a prospective cohort
Objective: To compare the maternal‐fetal/neonatal outcome in patients with systemic lupus erythematosus (SLE) with and without lupus nephritis (LN) in remission or with active disease. Methods: A prospective cohort of pregnant patients with SLE (ACR 1997 criteria) was studied from January 2009 to December 2021. Demographic, clinical, biochemical, and immunological variables as well as the usual maternal‐fetal/neonatal complications were recorded. We compared four groups according to the status of SLE during pregnancy: patients with quiescent SLE without lupus nephritis, patients with active SLE without lupus nephritis, patients with quiescent lupus nephritis, and patients with active lupus nephritis. Statistical analysis included descriptive statistics, bivariate analysis, and Cox regression analysis. Results: A total of 439 pregnancies were studied, with a median age of 28 ± 6, SLE duration of 60 months (interquartile range 36–120). A higher frequency of maternal and fetal/neonatal complications was observed in patients with active SLE with or without lupus nephritis. Multivariate analysis showed that active LN was a risk factor for gestational hypertension (hazard ratios [HR] 1.95; 95% confidence intervals [CI]: 1.01–6.39), premature rupture of membranes (HR 3.56; 95% CI: 1.79–16.05) and more frequent cesarean section (HR 1.82; 95% CI: 1.13–2.94). Conclusion: LN is associated with a higher frequency of maternal complications, especially in those patients with active disease during pregnancy, and those maternal complications had an impact on poor fetal/neonatal outcomes. Strict control and timely care of LN could improve the obstetric prognosis.
- 30 September 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (12) , 2221-2231
In-hospital mortality and associated factors in patients with systemic lupus erythematosus: analysis over more than 11 years in a reference hospital center
Systemic lupus erythematosus (SLE) is a disease that affects the immune system, and it can lead to increased morbidity and mortality. The primary causes of mortality for individuals with SLE are disease activity, infections, drug toxicity, and other health conditions. The aim of this study is to estimate the mortality rate of patients with SLE who are hospitalized, describe the causes of death, and identify factors associated with mortality. The study was conducted at a referral hospital from 2009 to 2021, utilizing a nested case–control design. The records of patients with SLE who were hospitalized in the Department of Rheumatology were reviewed. Cases were identified as individuals who died during their hospitalization, while controls were those who were discharged alive during the same period. Elective hospitalizations were not included in the study. The primary causes of death were recorded, and demographic, clinical, laboratory, and immunological variables were analyzed as potential risk factors associated with in-hospital mortality. The study included 105 patients who died while hospitalized and 336 who were discharged alive. The estimated mortality rate was 10.93 deaths per 1000 hospital admissions per year. The leading causes of death were SLE activity (20%), infections (34.2%), or a combination of both (24.8%). Risk factors associated with in-hospital mortality were any infection (OR 2.5, CI 95% 1.2–5.2), nosocomial infections (OR 5.0, CI 95% 1.8–13.7), SLEDAI-2K > 2 (OR 2.0, CI 95% 1.02–3.8), lymphopenia (OR 2.1, CI 95% 1.01–4.6), anemia (OR 2.9, CI 95% 1.4–5.7), and thrombocytopenia (OR 3.3, CI 95% 1.7–6.4). Disease activity and infections, particularly nosocomial infections, are significant causes of mortality in hospitalized patients with SLE. Furthermore, hematological manifestations play a significant role in in-hospital mortality for these patients.
- 30 September 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (12) , 2221-2231
In-hospital mortality and associated factors in patients with systemic lupus erythematosus: analysis over more than 11 years in a reference hospital center
Systemic lupus erythematosus (SLE) is a disease that affects the immune system, and it can lead to increased morbidity and mortality. The primary causes of mortality for individuals with SLE are disease activity, infections, drug toxicity, and other health conditions. The aim of this study is to estimate the mortality rate of patients with SLE who are hospitalized, describe the causes of death, and identify factors associated with mortality. The study was conducted at a referral hospital from 2009 to 2021, utilizing a nested case–control design. The records of patients with SLE who were hospitalized in the Department of Rheumatology were reviewed. Cases were identified as individuals who died during their hospitalization, while controls were those who were discharged alive during the same period. Elective hospitalizations were not included in the study. The primary causes of death were recorded, and demographic, clinical, laboratory, and immunological variables were analyzed as potential risk factors associated with in-hospital mortality. The study included 105 patients who died while hospitalized and 336 who were discharged alive. The estimated mortality rate was 10.93 deaths per 1000 hospital admissions per year. The leading causes of death were SLE activity (20%), infections (34.2%), or a combination of both (24.8%). Risk factors associated with in-hospital mortality were any infection (OR 2.5, CI 95% 1.2–5.2), nosocomial infections (OR 5.0, CI 95% 1.8–13.7), SLEDAI-2K > 2 (OR 2.0, CI 95% 1.02–3.8), lymphopenia (OR 2.1, CI 95% 1.01–4.6), anemia (OR 2.9, CI 95% 1.4–5.7), and thrombocytopenia (OR 3.3, CI 95% 1.7–6.4). Disease activity and infections, particularly nosocomial infections, are significant causes of mortality in hospitalized patients with SLE. Furthermore, hematological manifestations play a significant role in in-hospital mortality for these patients.
- 1 October 2018
- Published by Elsevier in Pharmacological Research
- Vol. 136, 21-28
Targeted drugs in spondyloarthritis during pregnancy and lactation
- 1 October 2018
- Published by Elsevier in Pharmacological Research
- Vol. 136, 21-28
Targeted drugs in spondyloarthritis during pregnancy and lactation
- Open Access
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 860
SAT0229 The use of antimalarial drugs during pregnancy can prevent the development of preeclampsia in women with systemic lupus erythematosus
Background The antimalarial drugs decrease the risk of lupus activity during gestation, but the beneficial effect on other maternal-fetal complications is controversial. Objectives To analyze the beneficial effect of antimalarial drugs on maternal-fetal complications in pregnant women with systemic lupus erythematosus (SLE). Methods A prospective cohort of pregnant women with SLE (ACR 1997) from January 2009 to June 2015 was studied. The patients were assessed every 4 to 6 weeks and postpartum both, by a rheumatologist and a gynecologist. Clinical, biochemical, and immunological characteristics, along with maternal and fetal complications were registered. For analysis, the patients were allocated to one of two groups: pregnancies exposed to antimalarial drugs in comparison to those not exposed. A logistic regression analysis including variables such as smoking, obesity, infections, first pregnancy, age, SLE flare, drugs (prednisone, antimalarials, aspirin, and azathioprine), anti-DNA antibodies, anticardiolipin antibodies, and antiphospholipid syndrome was performed. Results We studied 197 lupus pregnancies, 154 expose to antimalarial drugs and 47 unexposed. We found no differences between groups in age, years of evolution of SLE, first pregnancy, childhood-onset SLE, lupus nephritis, and use of prednisone, aspirin and azathioprine. The rate of most maternal and fetal complications was also similar in both groups (Table). A lower incidence of preeclampsia was observed in patients exposed to antimalarial drugs compared to those not exposed (9% vs 23%, p=0.01). Additionally, 2 maternal deaths in patients not exposed to antimalarial drugs. The logistic regression analysis showed that the use of antimalarial drugs during pregnancy is a protective factor for the development of preeclampsia (RR 0.1, 95% CI 0.05–0.58, p=0.004); on the other hand, active SLE before pregnancy (RR 4.8, 95% CI 1.3–17.8, p=0.01) and lupus nephritis (RR 2.9, 95% CI 0.9–8.8, p=0.05) were associated factors with the development of preeclampsia. Maternal and fetal outcomes Conclusions Our study suggests that the use of antimalarial drugs during pregnancy can prevent the development of preeclampsia in women with SLE. Disclosure of Interest None declared
- 1 June 2017
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 76 (Suppl 2) , 860
Open AccessSAT0229 The use of antimalarial drugs during pregnancy can prevent the development of preeclampsia in women with systemic lupus erythematosus
Background The antimalarial drugs decrease the risk of lupus activity during gestation, but the beneficial effect on other maternal-fetal complications is controversial. Objectives To analyze the beneficial effect of antimalarial drugs on maternal-fetal complications in pregnant women with systemic lupus erythematosus (SLE). Methods A prospective cohort of pregnant women with SLE (ACR 1997) from January 2009 to June 2015 was studied. The patients were assessed every 4 to 6 weeks and postpartum both, by a rheumatologist and a gynecologist. Clinical, biochemical, and immunological characteristics, along with maternal and fetal complications were registered. For analysis, the patients were allocated to one of two groups: pregnancies exposed to antimalarial drugs in comparison to those not exposed. A logistic regression analysis including variables such as smoking, obesity, infections, first pregnancy, age, SLE flare, drugs (prednisone, antimalarials, aspirin, and azathioprine), anti-DNA antibodies, anticardiolipin antibodies, and antiphospholipid syndrome was performed. Results We studied 197 lupus pregnancies, 154 expose to antimalarial drugs and 47 unexposed. We found no differences between groups in age, years of evolution of SLE, first pregnancy, childhood-onset SLE, lupus nephritis, and use of prednisone, aspirin and azathioprine. The rate of most maternal and fetal complications was also similar in both groups (Table). A lower incidence of preeclampsia was observed in patients exposed to antimalarial drugs compared to those not exposed (9% vs 23%, p=0.01). Additionally, 2 maternal deaths in patients not exposed to antimalarial drugs. The logistic regression analysis showed that the use of antimalarial drugs during pregnancy is a protective factor for the development of preeclampsia (RR 0.1, 95% CI 0.05–0.58, p=0.004); on the other hand, active SLE before pregnancy (RR 4.8, 95% CI 1.3–17.8, p=0.01) and lupus nephritis (RR 2.9, 95% CI 0.9–8.8, p=0.05) were associated factors with the development of preeclampsia. Maternal and fetal outcomes Conclusions Our study suggests that the use of antimalarial drugs during pregnancy can prevent the development of preeclampsia in women with SLE. Disclosure of Interest None declared
- 1 January 2015
- p. S24-9
[Maternal and fetal outcome in Mexican women with rheumatoid arthritis].
To report our experience in maternal-fetal outcome in women with RA in a national medical referral center. A retrospective analysis of the records of pregnant women with rheumatoid arthritis attending at a Pregnancy and Autoimmune Rheumatic Diseases Clinic was performed. Maternal-fetal outcomes such as disease activity, preclampsia/eclampsia, rate of live births, abortions, stillbirths, preterm birth, weeks of gestation, birth weight, congenital malformations and use of anti-rheumatic drugs were studied. We included 73 pregnancies in 72 patients. Disease activity was documented in 47.2% of patients during pregnancy and/or postpartum and 87.7% of patients received some antirheumatic drug. Preclampsia developed in 8.2% of cases. The live birth rate was 98.6%, with preterm delivery in 15.9% and low weight at term in 17.6% of cases. Cesarean section was performed in 77.1% of cases. The disease activity was not associated with a higher percentage of maternal-fetal complications. Our study showed that most patients do not experience significant activity of RA during pregnancy, fetal outcome is satisfactory and disease activity did not appear to influence significantly the obstetric outcome.
- 1 January 2015
- p. S24-9
[Maternal and fetal outcome in Mexican women with rheumatoid arthritis].
To report our experience in maternal-fetal outcome in women with RA in a national medical referral center. A retrospective analysis of the records of pregnant women with rheumatoid arthritis attending at a Pregnancy and Autoimmune Rheumatic Diseases Clinic was performed. Maternal-fetal outcomes such as disease activity, preclampsia/eclampsia, rate of live births, abortions, stillbirths, preterm birth, weeks of gestation, birth weight, congenital malformations and use of anti-rheumatic drugs were studied. We included 73 pregnancies in 72 patients. Disease activity was documented in 47.2% of patients during pregnancy and/or postpartum and 87.7% of patients received some antirheumatic drug. Preclampsia developed in 8.2% of cases. The live birth rate was 98.6%, with preterm delivery in 15.9% and low weight at term in 17.6% of cases. Cesarean section was performed in 77.1% of cases. The disease activity was not associated with a higher percentage of maternal-fetal complications. Our study showed that most patients do not experience significant activity of RA during pregnancy, fetal outcome is satisfactory and disease activity did not appear to influence significantly the obstetric outcome.
- 1 May 2014
- Published by Elsevier in Reumatología Clínica
- Vol. 10 (3) , 164-169
Predictores de respuesta al tratamiento en pacientes con nefritis lúpica
- 1 May 2014
- Published by Elsevier in Reumatología Clínica
- Vol. 10 (3) , 164-169
Predictores de respuesta al tratamiento en pacientes con nefritis lúpica